New therapeutic approaches to mendelian disorders.

Thanks to the power of a method to identify etiologic mutations (and hence “causative” genes) in mendelian disease, the molecular mechanisms that give rise to many such diseases are now known. This knowledge has fueled new therapeutic approaches, which are reviewed in this article, the third in the Genomic Medicine series.

[1]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[2]  A. Bárez,et al.  Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project , 2009, Haematologica.

[3]  B. Bembi,et al.  Miglustat (Zavesca®) in type 1 Gaucher disease: 5‐year results of a post‐authorisation safety surveillance programme , 2009, Pharmacoepidemiology and drug safety.

[4]  H. Dietz,et al.  Circulating Transforming Growth Factor-&bgr; in Marfan Syndrome , 2009, Circulation.

[5]  A. J. Roman,et al.  Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. , 2009, Human gene therapy.

[6]  P. Conn,et al.  Drug development and the cellular quality control system. , 2009, Trends in pharmacological sciences.

[7]  A. Al Haj Zen,et al.  Syndromic and non‐syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway , 2009, The Journal of pathology.

[8]  P. Morcos,et al.  Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  M. Rapoport,et al.  TAT-based drug delivery system – new directions in protein delivery for new hopes? , 2009 .

[10]  D. Klionsky.  Crohn's disease, autophagy, and the Paneth cell. , 2009, The New England journal of medicine.

[11]  D. Mahuran,et al.  Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. , 2009, Molecular genetics and metabolism.

[12]  S. Rodríguez de Córdoba,et al.  Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B , 2009, Proceedings of the National Academy of Sciences.

[13]  D. Auld,et al.  Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression , 2009, Proceedings of the National Academy of Sciences.

[14]  G. van Ommen,et al.  Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.

[15]  M. Roncarolo,et al.  Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID , 2009, Immunologic research.

[16]  S. Kurata,et al.  An unexpected twist for autophagy in Crohn's disease , 2009, Nature Immunology.

[17]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[18]  R. Schiffmann,et al.  Randomized, controlled trial of miglustat in Gaucher's disease type 3 , 2008, Annals of neurology.

[19]  J. Rosenbloom,et al.  Angiotensin II blockade in Marfan's syndrome. , 2008, The New England journal of medicine.

[20]  F. Collins,et al.  A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model , 2008, Proceedings of the National Academy of Sciences.

[21]  John R. Yates,et al.  Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases , 2008, Cell.

[22]  Eitan Kerem,et al.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.

[23]  K. Ponder.  Immune response hinders therapy for lysosomal storage diseases. , 2008, The Journal of clinical investigation.

[24]  C. Reggiani,et al.  In vivo delivery of naked antisense oligos in aged mdx mice: Analysis of dystrophin restoration in skeletal and cardiac muscle , 2008, Neuromuscular Disorders.

[25]  D. Begley,et al.  Lysosomal storage diseases and the blood-brain barrier. , 2008, Current pharmaceutical design.

[26]  M. Radomski,et al.  Long-Term Doxycycline Is More Effective Than Atenolol to Prevent Thoracic Aortic Aneurysm in Marfan Syndrome Through the Inhibition of Matrix Metalloproteinase-2 and -9 , 2008, Circulation research.

[27]  C. Ficicioglu.  Review of miglustat for clinical management in Gaucher disease type 1 , 2008, Therapeutics and clinical risk management.

[28]  S. Peltz,et al.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.

[29]  D. Fowler,et al.  Partial Restoration of Mutant Enzyme Homeostasis in Three Distinct Lysosomal Storage Disease Cell Lines by Altering Calcium Homeostasis , 2008, PLoS biology.

[30]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[31]  S. Colan,et al.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.

[32]  R. Gibson,et al.  No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. , 2007, American journal of respiratory cell and molecular biology.

[33]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[34]  L. Notarangelo,et al.  Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). , 2007, Clinical immunology.

[35]  S. Peltz,et al.  Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers , 2007, Journal of clinical pharmacology.

[36]  H. Dietz,et al.  Perturbations of Vascular Homeostasis and Aortic Valve Abnormalities in Fibulin-4 Deficient Mice , 2007, Circulation research.

[37]  D. Judge,et al.  Therapy for Marfan Syndrome , 2006, Science.

[38]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[39]  H. Dietz,et al.  Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome , 2006, Nature Genetics.

[40]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[41]  M. Gelb,et al.  Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[43]  J. Lemontt,et al.  Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[45]  C. Mann,et al.  Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.

[46]  Laura Scott,et al.  Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome , 2003, Nature.

[47]  G. Piluso,et al.  Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. , 2003, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[48]  Hanns Lochmüller,et al.  Gentamicin fails to increase dystrophin expression in dystrophin‐deficient muscle , 2003, Muscle & nerve.

[49]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[50]  Kathryn A. O’Donnell,et al.  An mRNA Surveillance Mechanism That Eliminates Transcripts Lacking Termination Codons , 2002, Science.

[51]  K. Fischbeck,et al.  Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations , 2001, Annals of neurology.

[52]  J. Thompson,et al.  Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. , 2001, Human molecular genetics.

[53]  C. Mann,et al.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Parker,et al.  Recognition of yeast mRNAs as "nonsense containing" leads to both inhibition of mRNA translation and mRNA degradation: implications for the control of mRNA decapping. , 1999, Molecular biology of the cell.

[55]  H. Sweeney,et al.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. , 1999, The Journal of clinical investigation.

[56]  J. Clancy,et al.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line , 1997, Nature Medicine.

[57]  N. Radin.  Treatment of Gaucher disease with an enzyme inhibitor , 1996, Glycoconjugate Journal.

[58]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[59]  M. Briley.  An unexpected twist , 1993 .

[60]  S. Peltz,et al.  The product of the yeast UPF1 gene is required for rapid turnover of mRNAs containing a premature translational termination codon. , 1991, Genes & development.

[61]  S. Kornfeld.  Trafficking of lysosomal enzymes 1 , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  J. Burke,et al.  Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. , 1985, Nucleic acids research.

[63]  E. Neufeld,et al.  A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes. , 1972, Biochemical and biophysical research communications.

[64]  C. W. Hall,et al.  Hurler and Hunter Syndromes: Mutual Correction of the Defect in Cultured Fibroblasts , 1968, Science.

[65]  B. Thiers.  Phenotype and Course of Hutchinson–Gilford Progeria Syndrome , 2009 .

[66]  A. Mehta,et al.  Goal-oriented therapy with miglustat in Gaucher disease. , 2009, Current medical research and opinion.

[67]  S. Young,et al.  Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. , 2008, Biochimica et biophysica acta.

[68]  Jian‐Qiang Fan,et al.  A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity , 2008, Biological chemistry.

[69]  B. Baxter,et al.  Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. , 2008, Journal of vascular surgery.

[70]  J. Stockman.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2008 .

[71]  Yang Pc,et al.  (Am. J. Respir. Cell Mol. Biol., 32:540-547)Autocrine and Paracrine Regulation of IL-8 Expression in Lung Cancer Cells , 2005 .

[72]  G. van Ommen,et al.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.

[73]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[74]  D. Sleat,et al.  Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[75]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[76]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[77]  S. Kornfeld.  Trafficking of lysosomal enzymes in normal and disease states. , 1986, The Journal of clinical investigation.